The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Fluvoxamine Treatment of Social Phobia (Social Anxiety Disorder): A Double-Blind, Placebo-Controlled Study
Abstract
OBJECTIVE: The purpose of this study was to determine the efficacy of fluvoxamine for the treatment of social phobia (social anxiety disorder). METHOD: In a 12-week multicenter, double-blind, randomized, placebo-controlled trial, 92 patients with social phobia were treated with the selective serotonin reuptake inhibitor fluvoxamine; 91.3% of the patients had the generalized subtype of the disorder. The primary criterion for response was a rating of "much improved" or "very much improved" on the Clinical Global Impression of Improvement scale. Secondary response criteria were changes on three specialized rating scales for social phobia symptoms: the Brief Social Phobia Scale, the Social Phobia Inventory, and the Liebowitz Social Anxiety Scale. Psychosocial impairment was assessed in three domains (disruption of work, social life, and home/family life) by using the Sheehan Disability Scale. RESULTS: The mean daily dose of fluvoxamine was 202 mg (SD = 86). At study end or with the last observation carried forward, within the evaluable subjects (N = 86) there was a significantly higher proportion of responders in the fluvoxamine group (42.9%, N = 18) than in the placebo group (22.7%, N = 10). Similarly, fluvoxamine was superior to placebo on all social phobia rating scales at week 8 and beyond. Fluvoxamine also resulted in significantly greater decreases in measures of psychosocial disability than did placebo. Overall, fluvoxamine was well tolerated and safe. CONCLUSIONS: These findings indicate that fluvoxamine is efficacious in the pharmacologic management of serious forms of social phobia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Liebowitz, M. R. (2015) · Modern Trends in Pharmacopsychiatry · doi:10.1159/000414022 · Cited by 2,266
Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey
Magee, W. J. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830020077009 · Cited by 996
Functional impairment in social phobia.
Schneier, F. R., Heckelman, L., Garfinkel, R. S., Campeas, R. B., Fallon, B. A., Gitow, A., Street, L. L., Bene, D. D., & Liebowitz, M. R. (1994) · PubMed · Cited by 534
Phenelzine vs Atenolol in Social Phobia: A Placebo-Controlled Comparison
Liebowitz, M. R., Schneier, F., Campeas, R., Hollander, E., Hatterer, J., Fyer, A., Gorman, J., Papp, L., Davies, S., Gully, R., et al. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.49.4.290 · Cited by 444
Self-citationCognitive-Behavioral and Pharmacological Treatments of Social Phobia: A Controlled Study
Gelernter, C. S. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810340070009 · Cited by 404
Social Phobia Subtypes in the National Comorbidity Survey
Kessler, R. C., Stein, M. B., & Berglund, P. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.5.613 · Cited by 398
Self-citationStein, M. B., Liebowitz, M. R., Lydiard, R. B., Pitts, C. D., Bushnell, W., & Gergel, I. (1998) · JAMA · doi:10.1001/jama.280.8.708 · Cited by 348
Self-citationPharmacotherapy of Social Phobia: A Controlled Study with Moclobemide and Phenelzine
Versiani, M., Nardi, A. E., Mundim, F. D., Alves, A. B., Liebowitz, M. R., & Amrein, R. (1992) · British Journal of Psychiatry · doi:10.1192/bjp.161.3.353 · Cited by 333
Assessing impairment in patients with panic disorder: the Sheehan Disability Scale
Leon, A. C., Shear, M. K., Portera, L., & Klerman, G. L. (1992) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/bf00788510 · Cited by 319
Cited by
Psychometric properties of the Social Phobia Inventory (SPIN): New self-rating scale
Connor, K. M., Davidson, J. R. T., Churchill, L. E., Sherwood, A., Weisler, R. H., & Foa, E. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.4.379 · Cited by 1,624
Self-citationStein, M. B., & Stein, D. J. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60488-2 · Cited by 1,137
Self-citationKatzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
(2008) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.149114 · Cited by 1,028
Quality of Life in Individuals With Anxiety Disorders
Mendlowicz, M. V., & Stein, M. B. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.669 · Cited by 955
Self-citationQuality of life in the anxiety disorders: a meta-analytic review
Olatunji, B. O., Cisler, J. M., & Tolin, D. F. (2007) · Clinical Psychology Review · doi:10.1016/j.cpr.2007.01.015 · Cited by 808
The Liebowitz social anxiety scale as a self-report instrument: a preliminary psychometric analysis
Baker, S. L., Heinrichs, N., Kim, H.-J., & Hofmann, S. G. (2002) · Behaviour Research and Therapy · doi:10.1016/s0005-7967(01)00060-2 · Cited by 640
Clark, D. M., Ehlers, A., McManus, F., Hackmann, A., Fennell, M., Campbell, H., Flower, T., Davenport, C., & Louis, B. (2003) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.71.6.1058 · Cited by 561
Sheehan, K. H., & Sheehan, D. V. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f2b4d6 · Cited by 467
Rytwinski, N. K., Fresco, D. M., Heimberg, R. G., Coles, M. E., Liebowitz, M. R., Cissell, S., Stein, M. B., & Hofmann, S. G. (2009) · Depression and Anxiety · doi:10.1002/da.20503 · Cited by 432
Self-citationThe treatment of social anxiety disorder
Rodebaugh, T. L., Holaway, R. M., & Heimberg, R. G. (2004) · Clinical Psychology Review · doi:10.1016/j.cpr.2004.07.007 · Cited by 424
Psychological and Pharmacological Treatments of Social Phobia: A Meta-Analysis
Fedoroff, I. C., & Taylor, S. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200106000-00011 · Cited by 396
Update on Bispectral Index monitoring
Johansen, J. W. (2006) · Best Practice & Research Clinical Anaesthesiology · doi:10.1016/j.bpa.2005.08.004 · Cited by 313
Psychometric properties of the social phobia inventory: Further evaluation
Antony, M. M., Coons, M. J., McCabe, R. E., Ashbaugh, A., & Swinson, R. P. (2006) · Behaviour Research and Therapy · doi:10.1016/j.brat.2005.08.013 · Cited by 299
Romero, L. M., & Remage-Healey, L. (2000) · General and Comparative Endocrinology · doi:10.1006/gcen.2000.7491 · Cited by 259
Social Anxiety Disorder: (532272011-001)
(2008) · PsycEXTRA Dataset · doi:10.1037/e532272011-001 · Cited by 258
Social anxiety disorder in childhood and adolescence: Current status and future directions
Kashdan, T. B., & Herbert, J. D. (2001) · Clinical Child and Family Psychology Review · doi:10.1023/a:1009576610507 · Cited by 205
Rief, W., Nestoriuc, Y., von Lilienfeld-Toal, A., Dogan, I., Schreiber, F., Hofmann, S. G., Barsky, A. J., & Avorn, J. (2009) · Drug Safety · doi:10.2165/11316580-000000000-00000 · Cited by 202
“A total of 143 studies([14-155]) 2 including 12 742 patients (11 719 in SSRI placebo groups, 1023 in TCA placebo groups) were analysed (see figure 1).”
BackgroundAnxiety disorders: a comprehensive review of pharmacotherapies
Hoffman, E. J., & Mathew, S. J. (2008) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20041 · Cited by 149
Systematic review and meta-analysis: dose-response curve of SSRIs and SNRIs in anxiety disorders
Jakubovski, E., Johnson, J. A., Nasir, M., Müller-Vahl, K., & Bloch, M. H. (2019) · Depression and Anxiety · doi:10.1002/da.22854 · Cited by 131
Unmet need for services and interventions among adolescents with mental disorders
Wang, P. S., Sherrill, J., & Vitiello, B. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.1.1 · Cited by 123
The evidence-based pharmacotherapy of social anxiety disorder
Blanco, C., Bragdon, L. B., Schneier, F. R., & Liebowitz, M. R. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000119 · Cited by 99
Pharmacotherapy of social anxiety disorder
Blanco, C., Antia, S. X., & Liebowitz, M. R. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01294-x · Cited by 88
Pharmacotherapy for social anxiety disorder (SAnD)
Williams, T., Hattingh, C. J., Kariuki, C. M., Tromp, S. A., van Balkom, A. J., Ipser, J. C., & Stein, D. J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001206.pub3 · Cited by 84
Walker, J. R., Van Ameringen, M. A., Swinson, R., Bowen, R. C., Chokka, P. R., Goldner, E., Johnston, D. C., Lavallie, Y.-J., Nandy, S., Pecknold, J. C., et al. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200012000-00009 · Cited by 84
Evidence-based pharmacotherapy for personality disorders
Ripoll, L. H., Triebwasser, J., & Siever, L. J. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000071 · Cited by 83
Childhood Social Anxiety Disorder: From Understanding to Treatment
Chavira, D. A., & Stein, M. B. (2005) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2005.05.003 · Cited by 71
Self-citationPharmacotherapy of social phobia
Davidson, J. R. T. (2003) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.108.s417.7.x · Cited by 69
Social anxiety disorder/social phobia: Epidemiology, diagnosis, neurobiology, and treatment
den Boer, J. A. (2000) · Comprehensive Psychiatry · doi:10.1053/comp.2000.16564 · Cited by 67
Watanabe, N., Furukawa, T. A., Chen, J., Kinoshita, Y., Nakano, Y., Ogawa, S., Funayama, T., Ietsugu, T., & Noda, Y. (2010) · BMC Psychiatry · doi:10.1186/1471-244x-10-81 · Cited by 50
“In comparison with patients treated with placebo pills, several RCTs reported improvements in some QoL measures after treatment with a variety of antidepressants [15-17].”
ResultPharmacotherapy for Anxiety Disorders: From First-Line Options to Treatment Resistance
Melaragno, A. J. (2021) · Focus · doi:10.1176/appi.focus.20200048 · Cited by 50
Curtiss, J., Andrews, L., Davis, M., Smits, J., & Hofmann, S. G. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1285907 · Cited by 46
Nagata, T., Suzuki, F., & Teo, A. R. (2015) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12327 · Cited by 40
Stein, D., Stein, M., Goodwin, W., Kumar, R., & Hunter, B. (2001) · Psychopharmacology · doi:10.1007/s002130100880 · Cited by 39
Self-citationStrawn, J. R., & Levine, A. (2020) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2020.100024 · Cited by 30
MONTGOMERY, S. (2004) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.06.001 · Cited by 18
Quality of Life Impairment in Anxiety Disorders
Koury, M. A., & Rapaport, M. H. (2007) · Quality of Life Impairment in Schizophrenia, Mood and Anxiety Disorders · doi:10.1007/978-1-4020-5779-3_14 · Cited by 10
Psychopharmacology for Social Anxiety Disorder
Blanco, C., Bragdon, L., Schneier, F. R., & Liebowitz, M. R. (2014) · Social Anxiety · doi:10.1016/b978-0-12-394427-6.00022-4 · Cited by 2
Metadata
- Authors
- Stein, M. B., Fyer, A. J., Davidson, J. R. T., Pollack, M. H., & Wiita, B.
- Venue
- American Journal of Psychiatry
- Published
- 1999-05-01
- Volume
- 156
- Issue
- 5
- Pages
- 756-760
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2169621217
- Cited by
- 262
- References
- 26
- FWCI
- 35.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.